Editorial: Biology and treatment of high-risk CLL

Eugen Tausch; Jitka Malcikova; John C Riches; Jennifer Edelmann

doi:10.3389/fonc.2022.1109950

Editorial: Biology and treatment of high-risk CLL

Front Oncol. 2023 Feb 20:12:1109950. doi: 10.3389/fonc.2022.1109950. eCollection 2022.

Authors

Eugen Tausch¹, Jitka Malcikova^{2

3}, John C Riches^{4

5}, Jennifer Edelmann⁶

Affiliations

¹ Division of Chronic Lymphocytic Leukemia (CLL), Department of Internal Medicine III, Ulm University, Ulm, Germany.
² Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czechia.
³ Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czechia.
⁴ Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
⁵ Department of Haemato-Oncology, Barts Health NHS Trust, St. Bartholomew's Hospital, London, United Kingdom.
⁶ Ulm University Hospital, Ulm, Germany.

No abstract available

Keywords: TP53; chronic lymphocytic leukemia (CLL); high-risk; omics; registries; targeted therapy.

Publication types

Editorial

Grants and funding

Jitka Malcikova was supported by the project Conceptual development of research organization (FNBr 6526975) provided by the Ministry of Health of the Czech Republic and by the National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102) funded by the European Union – Next Generation EU. Jennifer Edelmann was invited to work on the Research Topic as an employee of the Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany and was supported by the Clinician Scientist Program of the Medical Faculty of Ulm University, Ulm, Germany at these times.